An observational study in Coronary Artery Disease, sponsored by Scitech Produtos Medicos Ltda. Completed at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-18.
Sponsored by Scitech Produtos Medicos Ltda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 30 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 18th largest by enrollment of the 28 observational ones that give a count, is one of 7 that started in 2018, is one of 29 observational ones, and was the 92nd registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:
Scitech Produtos Medicos SA · Sites in Brazil
Ages 18+
InCor Heart Institute · Sites in Brazil
Ages 45–70 · Women only
University of Sao Paulo General Hospital · Sites in Brazil
Ages 46–69 · Men only
Instituto Nacional de Cardiologia de Laranjeiras · Sites in Brazil
Ages 40–70 · Healthy volunteers
University of Sao Paulo General Hospital · Sites in Brazil
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 25 · Phase 4 17
First in 1999; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 299 is close to the median of 326 across 1,689 observational studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 123 interventional studies, 740 across the 28 observational. Of the 92 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 152 have an industry lead sponsor. The 10 most frequent:
Scitech Produtos Medicos Ltda is the lead sponsor of 13 studies on the registry; none are open to participants now.
Scitech Produtos Medicos Ltda has 9 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Artery Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579807Instituto Nacional de Cardiologia de LaranjeirasCardiac Rehabilitation and Coronary Artery Disease | 2026-12-31 |
| NCT07699679Federal University of São PauloPhotobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting. | 2027-08 |
| NCT07734831University of the State of Santa CatarinaTELEREHAB-BR: Cardiovascular Rehabilitation Models Trial | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.
Prospective, multicenter, single arm registry to assess the safety and performance of Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer for the treatment of "real world" patients.
Patients with lesions in native coronary arteries measuring between 2.5 and 4.0 mm in diameter and 34 mm length treated only with Inspiron Sirolimus-Eluting Stent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inspiron Drug Eluting stent implantation
MACE (major cardiac events)
Major cardiac events (death, myocardial infarction, target vessel revascularization)
Time frame: 12 months
Acute success
Acute success measured by Angiography after stent implantation
Time frame: up to 24 hours
Stent Thrombosis
Stent Thrombosis rate
Time frame: 24 months
MACE
Major cardiac events (death, myocardial infarction, target vessel revascularization)
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2018 to primary completion in Oct 2020, 25 months.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 25 months is close to that.
Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scitech Produtos Medicos Ltda